Viral oncolysate in the management of malignant melanoma.I. Preparation of the oncolysate and measurement of immunologic responses
- 1 August 1977
- Vol. 40 (2) , 672-679
- https://doi.org/10.1002/1097-0142(197708)40:2<672::aid-cncr2820400213>3.0.co;2-y
Abstract
Primary explants of human malignant melanoma were utilized in the preparation of oncolysates by Newcastle disease virus. The concentrated lysate, administered parenterally, was employed in an effort to augment antitumor immunologic responses in patients with metastatic melanoma. Observed cellular changes suggested a benefit, but humoral antibody measurements were not impressive. Cancer 40:672–679, 1977.This publication has 20 references indexed in Scilit:
- Melanoma Antigens That Produce Cell-Mediated Immune Responses in Melanoma Patients: Joint U.S.-U.S.S.R. StudyScience, 1975
- THYMUS-DEPENDENT LYMPHOCYTE LEVELS DURING RADIATION THERAPY FOR BRONCHOGENIC AND ESOPHAGEAL CARCINOMA: CORRELATIONS WITH CLINICAL COURSE IN RESPONDERS AND NONRESPONDERSAmerican Journal of Roentgenology, 1975
- Immunologic Approach to Cancer TherapyMedical Clinics of North America, 1975
- Virus-augmented tumor transplantation antigens: Evidence for a helper antigen mechanismInternational Journal of Cancer, 1974
- A standard method for DNCB sensitization testing in patients with neoplasmsCancer, 1974
- Identification of melanoma cells by formaldehyde-induced fluorescenceCancer, 1974
- Cell-Mediated Immunity to Tumor CellsAdvances in Cancer Research, 1974
- Preparation of Membrane Fractions With Enhanced Tumor-Transplantation-Antigen Activity From Tumor Cells Infected With Influenza VirusJNCI Journal of the National Cancer Institute, 1973
- Tumour Immunity induced in Mice with Cell-free Homogenates of Influenza Virus-infected Tumour CellsNature, 1971
- Newcastle disease virus as an antineoplastic agentCancer, 1965